Portage Biotech Inc (PRTG) concluded trading on Wednesday at a closing price of $6.11, with 4.18 million shares of worth about $25.53 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 4.44% during that period and on June 25, 2025 the price saw a gain of about 13.57%. Currently the company’s common shares owned by public are about 1.12M shares, out of which, 0.28M shares are available for trading.
Stock saw a price change of 6.45% in past 5 days and over the past one month there was a price change of -22.56%. Year-to-date (YTD), PRTG shares are showing a performance of 25.72% which increased to 18.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.10 but also hit the highest price of $23.01 during that period. The average intraday trading volume for Portage Biotech Inc shares is 1.35 million. The stock is currently trading -12.42% below its 20-day simple moving average (SMA20), while that difference is down -24.19% for SMA50 and it goes to 4.47% higher than SMA200.
Portage Biotech Inc (NASDAQ: PRTG) currently have 1.12M outstanding shares and institutions hold larger chunk of about 2.76% of that.
The stock has a current market capitalization of $6.85M and its 3Y-monthly beta is at 0.63. It has posted earnings per share of -$65.69 in the same period. It has Quick Ratio of 3.08 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PRTG, volatility over the week remained 7.43% while standing at 6.16% over the month.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on July 18, 2022 offering an Outperform rating for the stock and assigned a target price of $26 to it. Coverage by H.C. Wainwright stated Portage Biotech Inc (PRTG) stock as a Buy in their note to investors on March 07, 2022, suggesting a price target of $32 for the stock. On September 21, 2021, Oppenheimer Initiated their recommendations, while on September 02, 2021, B. Riley Securities Initiated their ratings for the stock with a price target of $40. Stock get an Overweight rating from Cantor Fitzgerald on August 19, 2021.
